MIST Milestone Pharmaceuticals Inc

Price (delayed)

$1.5

Market cap

$79.89M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.25

Enterprise value

$122.26M

Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of etripamil, a Phase 3 clinical-stage program, for the treatment of cardiovascular indications. Milestone Pharmaceuticals operates in Canada ...

Highlights
MIST's quick ratio has soared by 130% from the previous quarter and by 71% YoY
The EPS is up by 10% QoQ and by 10% YoY
The company's equity has surged by 138% QoQ but it fell by 26% YoY
The gross profit has dropped by 100% since the previous quarter and by 100% year-on-year
Milestone Pharmaceuticals's revenue has shrunk by 100% QoQ and by 100% YoY

Key stats

What are the main financial stats of MIST
Market
Shares outstanding
53.26M
Market cap
$79.89M
Enterprise value
$122.26M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$51.7M
EBITDA
-$51.6M
Free cash flow
-$41.53M
Per share
EPS
-$1.25
Free cash flow per share
-$0.83
Book value per share
$0.75
Revenue per share
$0
TBVPS
$1.91
Balance sheet
Total assets
$96M
Total liabilities
$56.08M
Debt
$52.51M
Equity
$39.92M
Working capital
$89.84M
Liquidity
Debt to equity
1.32
Current ratio
22.75
Quick ratio
22.01
Net debt/EBITDA
-0.82
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-62%
Return on equity
-175.4%
Return on invested capital
-44.2%
Return on capital employed
-56.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MIST stock price

How has the Milestone Pharmaceuticals stock price performed over time
Intraday
-1.32%
1 week
-9.09%
1 month
8.7%
1 year
-54.27%
YTD
-10.18%
QTD
12.78%

Financial performance

How have Milestone Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$56.07M
Net income
-$55.09M
Gross margin
N/A
Net margin
N/A
The gross profit has dropped by 100% since the previous quarter and by 100% year-on-year
Milestone Pharmaceuticals's revenue has shrunk by 100% QoQ and by 100% YoY
The operating income has grown by 8% from the previous quarter and by 8% YoY
The net income rose by 8% QoQ and by 7% YoY

Growth

What is Milestone Pharmaceuticals's growth rate over time

Valuation

What is Milestone Pharmaceuticals stock price valuation
P/E
N/A
P/B
2
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 10% QoQ and by 10% YoY
The company's equity has surged by 138% QoQ but it fell by 26% YoY
The P/B is 32% lower than the last 4 quarters average of 2.9 and 10% lower than the 5-year quarterly average of 2.2
Milestone Pharmaceuticals's revenue has shrunk by 100% QoQ and by 100% YoY

Efficiency

How efficient is Milestone Pharmaceuticals business performance
Milestone Pharmaceuticals's return on equity has shrunk by 110% YoY and by 2.6% QoQ
The ROIC has soared by 61% YoY and by 20% QoQ
MIST's ROA is up by 5% YoY and by 3.7% QoQ

Dividends

What is MIST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MIST.

Financial health

How did Milestone Pharmaceuticals financials performed over time
The total assets is 71% greater than the total liabilities
MIST's quick ratio has soared by 130% from the previous quarter and by 71% YoY
The current ratio has soared by 125% from the previous quarter and by 67% YoY
MIST's debt is 32% higher than its equity
The company's equity has surged by 138% QoQ but it fell by 26% YoY
MIST's debt to equity has dropped by 57% since the previous quarter but it is up by 43% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.